Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is demonstrating strong momentum with its Cabometyx product, which has seen a notable increase in market share, commanding 46% in the TRx market for renal cell carcinoma (RCC) and achieving a 15% year-over-year growth in TRx volume. The company is strategically expanding its gastrointestinal sales team to enhance its market presence and capitalize on the positive demand for Cabometyx, while also preparing for the launch of the promising drug zanzalintinib for colorectal cancer (CRC). Furthermore, Exelixis maintains a robust balance sheet and sustainable profitability, which sets it apart in the biopharmaceutical sector and supports its increasing sales forecasts through fiscal years 2026 to 2028.

Bears say

Exelixis Inc. has experienced a decline in its gross-to-net (GTN) percentage, decreasing from 30.2% in 3Q25 to 28.5% in 4Q25, primarily due to a drop in PHS/340B volume, which raises concerns about revenue stability. Despite achieving $545 million in Cabometyx sales for 4Q25, this figure fell short of both company and consensus estimates, indicating challenges in meeting growth expectations amid a competitive landscape in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Additionally, various risks, including commercial vulnerabilities related to Cabometyx and potential generic competition, along with uncertainties surrounding ongoing clinical trials, contribute to an overall negative outlook on Exelixis's stock performance.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.